This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Vagina, C52질의 악성신생물 (질암)

Special Copayment Reduction V193 — a copayment of 5% of covered medical care costs applies for 5 years from the date of cancer patient registration (the Cancer Control Act and the National Health Insurance special copayment reduction regulations)
Adult onset: very high | ICD-10: C52
Contents (Table of Contents)
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Primary vaginal carcinoma is one of the rarest gynecologic malignancies, and its historical description is not extensive. Until the early 20th century, most malignant lesions of the vagina were regarded as secondary invasion from cervical or vulvar cancer, and FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) formalized the definition of primary vaginal carcinoma in 1971. Criteria were established excluding from primary vaginal carcinoma cases with contiguous invasion from the cervix or vulva, or cases diagnosed with cervical or vulvar cancer within 5 years.

Because there was no systematic clinical classification of primary vaginal carcinoma before 1971, interpreting historical data is complicated. In 1971, Herbst et al. reported an association between clear cell adenocarcinoma and prenatal diethylstilbestrol (DES) exposure, which shocked the medical community. DES was a synthetic estrogen used in the 1940s–1970s to prevent miscarriage, and girls exposed to DES in utero were found to have a dozens-fold increased risk of clear cell adenocarcinoma of the vagina. After DES use was banned, the related cancers decreased dramatically.

In the 1980s–1990s, the etiologic link between human papillomavirus (HPV) and vaginal squamous cell carcinoma began to be elucidated, and cases of vaginal intraepithelial neoplasia (VaIN) found during follow-up of abnormal cytology as part of cervical cancer screening programs increased. Since the 2000s, advances in molecular pathology and genomic analysis have begun to define molecular subtypes of vaginal cancer, and The Cancer Genome Atlas (TCGA) project compared the genomic profile of vaginal cancer with cervical cancer and reported substantial overlap. In 2025, FIGO and international academic bodies published "Cancer of the vagina: 2025 update," updating the latest molecular pathology and treatment guidelines.

In Korea, trends in gynecologic cancer incidence and survival for 1999–2019 were published based on Korea Central Cancer Registry (KCCR) data, and vaginal cancer was reported to have the lowest 5-year survival rate (56.6%) among all gynecologic cancers.

2. Causes

The main causes of primary vaginal carcinoma are broadly divided into HPV infection-related and non-HPV pathways. Squamous cell carcinoma (SCC) accounts for 85–90% of vaginal cancers, and the majority of these are closely associated with high-risk HPV infection.

HPV infection

High-risk HPV (HR-HPV), especially HPV types 16 and 18, is the key cause of vaginal high-grade squamous intraepithelial lesions (HSIL/VaIN 2-3) and invasive vaginal cancer. The HPV positivity rate is reported as about 91% in VaIN and about 86% in invasive vaginal squamous cell carcinoma. HPV promotes malignant transformation by degrading TP53 through the E6 protein and inactivating RB1 through the E7 protein, causing failure of cell cycle control.

Non-HPV risk factors

A past history of cervical or vulvar cancer increases the risk of HPV-related secondary lesions. Immunosuppression (HIV infection, immunosuppressant use after organ transplantation) significantly increases persistent HPV infection and the risk of VaIN/vaginal cancer. Radiation-induced malignant transformation can occur in the vagina after radiotherapy for cervical cancer. Chronic irritation of the vagina (chronic vaginitis, vaginal wall injury related to uterine prolapse) and smoking are also reported risk factors.

Congenital risk factor (DES exposure)

With a history of in utero DES exposure (born 1940–1971), the risk of clear cell adenocarcinoma of the vagina is increased. This generation has now mostly aged into their late 50s or older, but the concept of baseline risk has clinically important historical significance.

Other causes

Rarely, melanoma, sarcoma (sarcoma botryoides — embryonal rhabdomyosarcoma occurring in children), endocrine tumors, lymphoma and metastatic cancer (metastases from the uterus, rectum, bladder, ovary) may occur in the vagina.

3. Genetics

The genomic features of primary vaginal carcinoma overlap substantially with those of cervical cancer. HPV-positive and HPV-negative vaginal cancers show different molecular features.

Molecular features of HPV-positive vaginal cancer

Degradation of TP53 by the HPV E6 protein is the key mechanism, and separate somatic TP53 mutations are rare. PIK3CA mutation (about 30–40%) is reported as the most common somatic mutation, and activation of the PI3K/AKT/mTOR pathway is observed. PTEN deletion or inactivation activates the PI3K pathway together with or independently of PIK3CA mutation. EGFR amplification and overexpression are reported in some vaginal cancers. KRAS mutations are rare but observed in some adenocarcinomas.

Molecular features of HPV-negative vaginal cancer

Somatic TP53 mutations (about 60–70%) are very common, similar to HPV-negative vulvar cancer. HRAS mutations are also characteristically observed in the HPV-negative subtype. RB1 deletion or CDKN2A deletion may occur. These tumors tend to have a poorer prognosis than the HPV-positive subtype.

Chromosomal abnormalities and CNV

3q26 amplification (PIK3CA, SOX2, TP63) is characteristically observed in HPV-positive squamous cell carcinoma. 3p deletion (FHIT gene), 11q deletion, 9p deletion (CDKN2A) and others are reported. PD-L1 (CD274) overexpression is observed in some vaginal cancers and is a potential target for immune checkpoint inhibitor therapy.

MMR deficiency

Microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) is relatively rare in vaginal cancer, but dMMR-positive cases may respond to pembrolizumab therapy.

Genetic features of clear cell adenocarcinoma

ARID1A mutations are reported in DES-related clear cell adenocarcinoma, and PIK3CA and TP53 mutations are also observed. TCGA analysis shows molecular features similar to clear cell endometrial carcinoma.

4. General epidemiology

Primary vaginal carcinoma is the rarest gynecologic malignancy, accounting for about 1–2% of all gynecologic cancers. It must be clearly distinguished from secondary invasion of the vagina from cervical or vulvar cancer.

Global situation

Worldwide, about 18,000–20,000 people are diagnosed with primary vaginal carcinoma each year. In the United States, about 1,000–1,200 are diagnosed annually, corresponding to about 1% of gynecologic cancers. The median age at diagnosis is about 67 years (range 40–80), and it occurs mainly in postmenopausal women. Squamous cell carcinoma accounts for 85–90%, adenocarcinoma for 5–10%, and other histologic types such as melanoma and sarcoma for less than 5%.

Situation in Korea

In Korea, primary vaginal carcinoma is an extremely rare cancer with about 100–200 cases per year, less than about 1% of all gynecologic cancers. In the KCCR 1999–2019 analysis, the age-standardized incidence rate (AAPC) of vaginal cancer remained without significant change, while cervical cancer decreased and uterine corpus and ovarian cancers showed increasing trends. The 5-year survival rate of vaginal cancer was 56.6%, the lowest among the major gynecologic cancers (cervical cancer 80.4%, ovarian cancer 65.7%, uterine corpus cancer 84.4%, vulvar cancer 77.5%).

Racial differences

In the United States, the incidence of vaginal cancer is higher in Black women than in White women, which is analyzed as the combined effect of differences in HPV infection rates, access to care and screening rates.

CategoryFigureNotes
Global incidence~18,000–20,000 per yearAbout 1–2% of gynecologic cancers
Median age at diagnosis67 yearsMainly postmenopausal women
Korean 5-year survival rate56.6%KCCR 1999–2019 data
Proportion of squamous cell carcinoma85~90%Mostly HPV-related
HPV positivity rate (VaIN)91.2%Mainly HPV 16/18
HPV positivity rate (vaginal SCC)85.7%Driven by high-risk HPV

5. Pathophysiology

The pathophysiology of primary vaginal carcinoma is broadly divided into HPV-dependent and HPV-independent pathways. These two pathways are clearly distinct genomically and histopathologically.

HPV-dependent pathway

After high-risk HPV (mainly HPV 16) infects vaginal squamous cells, the viral genome integrates into the host chromosome. The E6 protein binds the E6AP ubiquitin ligase and degrades the TP53 protein, disabling the protective apoptosis function upon DNA damage. The E7 protein binds pRb (retinoblastoma protein) and releases the E2F transcription factor, thereby releasing the G1/S cell cycle checkpoint and promoting abnormal cell proliferation. HPV infection first causes low-grade squamous intraepithelial lesions (LSIL, formerly VaIN 1), which, with persistent infection and reduced immunity, progress to high-grade squamous intraepithelial lesions (HSIL, VaIN 2-3) and then develop into invasive cancer. Development of VaIN in residual HPV-infected epithelium at the vaginal opening after cervical LEEP (Loop Electrosurgical Excision Procedure) or conization is also an important mechanism.

HPV-independent pathway

HPV-negative vaginal cancer arising in elderly women undergoes malignant transformation through somatic TP53 mutation against a background of chronic irritation or atrophic vaginitis. In this pathway, HRAS activating mutations, RB1 deletion and CDKN2A deletion are characteristically observed. In malignant transformation after irradiation, double-strand DNA breaks cause genomic instability, leading to accumulation of various genetic abnormalities.

Pathophysiology of adenocarcinoma

DES exposure-related clear cell adenocarcinoma is understood to arise when excessive estrogen stimulation during development by in utero DES forms vaginal glandular tissue (adenosis), in which malignant transformation occurs. In non-DES-related adenocarcinoma, endocrine stimulation and gene variants such as ARID1A are presumed to be involved. Adenocarcinomas originating from mesonephric (Wolffian duct) remnants are also rarely reported.

6. Symptoms

Symptoms of primary vaginal carcinoma are often nonspecific, and it is frequently asymptomatic early, sometimes found incidentally during cervical cancer screening.

Main symptoms

The timing of symptom onset varies with tumor location, size, depth of invasion and histologic type. Cancers arising in the upper third of the vagina tend to invade the cervix or bladder earlier than those in the lower third.

7. Signs

The following findings may be observed on physical and gynecologic examination.

Gynecologic examination findings

Signs of pelvic invasion

Signs of metastasis

8. Screening

There is currently no officially recognized national screening program for primary vaginal carcinoma. However, because vaginal cancer is often diagnosed after abnormal findings during cervical cancer screening, this effectively serves as opportunistic detection.

Cervical cytology (Pap smear)

When cervical cytology or liquid-based cytology (LBC) shows abnormal findings such as ASC-H (atypical squamous cells, cannot exclude HSIL), HSIL or AGC (atypical glandular cells), colposcopy follows. Continuing vaginal cytology after hysterectomy is recommended, especially with HPV-related disease or a history of cervical cancer.

Colposcopy

When colposcopy shows acetowhitening, mosaic or punctation patterns on the vaginal epithelium, VaIN or early invasive cancer is suspected and a biopsy is taken. With iodine solution (Schiller test), iodine-negative areas are targeted for biopsy.

Surveillance of high-risk groups

9. Diagnosis

Histological diagnosis

The final diagnosis is histopathologic confirmation by tissue biopsy. Colposcopy-guided targeted biopsy is most accurate, and direct biopsy is possible for grossly obvious lesions. For diffuse lesions, four-quadrant biopsy is performed.

Imaging

FIGO staging (2021)

StageDefinition
Stage ITumor confined to the vaginal wall
Stage IITumor invades beyond the vaginal wall toward the pelvic wall, but does not reach the pelvic wall
Stage IIITumor reaches the pelvic wall and/or invades the lower third of the vagina and/or hydronephrosis/nonfunctioning kidney
Stage IVAInvasion of the bladder mucosa or rectal mucosa and/or direct extension beyond the true pelvis
Stage IVBDistant metastasis

Pathologic classification

10. Treatment

Treatment of vaginal cancer is individualized according to stage, tumor location (upper vs. lower vagina), size, histologic type, the patient's general condition and operability.

Surgical treatment

Radiation Therapy

In most vaginal cancers, radiotherapy is used as primary treatment or as adjuvant to surgery.

Concurrent chemoradiotherapy (CCRT)

Following the standard treatment for cervical cancer, CCRT with weekly cisplatin 40 mg/m² given concurrently with pelvic radiotherapy is recommended as the standard treatment for locally advanced vaginal cancer. In an NCDB analysis of 8,222 patients, a significant survival benefit was confirmed, with a median OS of 56 months in the CCRT group versus 41 months in the radiotherapy-alone group (6.9% absolute improvement).

Systemic chemotherapy

Treatment of VaIN

11. Prognosis

The prognosis of vaginal cancer depends greatly on stage at diagnosis and treatment method, and overall prognosis tends to be poorer than for other gynecologic cancers.

Cause-specific survival by stage

FIGO stage5-year cause-specific survival10-year cause-specific survival
Stage I96%96%
Stage II75%68%
Stage III69%64%
Stage IVA53%53%
Korea overall (1999–2019)56.6%—

Prognostic factors

12. Prevention

HPV vaccination

A substantial proportion of vaginal cancers caused by high-risk HPV can be prevented by HPV vaccination. Korea's National Immunization Program (NIP) has provided 2 doses of bivalent or quadrivalent HPV vaccine free of charge to girls aged 12 since 2016, with vaccination coverage reaching about 74% as of 2023. The 9-valent HPV vaccine (Gardasil 9) protects against 7 cancer-related HPV types (16, 18, 31, 33, 45, 52, 58) and is expected to provide broader protection.

Continued cervical cancer screening

Even after hysterectomy, regular vaginal cytology in those with HPV infection or a history of cervical cancer can detect VaIN and early vaginal cancer. The ESGO/ISSVD/EFC consensus guideline recommends cytology + HPV testing every 6 months for 2 years after treatment of VaIN 2+, then once a year.

Risk factor management

Early treatment of VaIN

Early treatment of VaIN 2–3 (HSIL) can prevent progression to invasive vaginal cancer. Patients with VaIN 1, in whom spontaneous regression is expected, also need regular follow-up.

13. References

  1. Adams TS, et al. Cancer of the vagina: 2025 update. Int J Gynecol Obstet. 2025. doi:10.1002/ijgo.70325
  2. Kim M, et al. Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and GTN in Korea, 1999-2019: KCCR. Obstet Gynecol Sci. 2023;66(6):545-554. PMC10663396
  3. Lagana AS, et al. Vaginal Intraepithelial Neoplasia (VaIN): A Retrospective Cohort Analysis. PMC12347765. 2025.
  4. ESGO/ISSVD/ECSVD/EFC Consensus Statement on Management of VaIN. PMC10026974. 2023.
  5. Hiniker SM, et al. Concurrent Chemoradiation for Vaginal Cancer. PMC3676389. Pract Radiat Oncol. 2013.
  6. Frank SJ, et al. Definitive Radiation Therapy for Primary Vaginal Carcinoma. Int J Radiat Oncol Biol Phys. 2014;89(3):648-657.
  7. Korean Society of Gynecologic Oncology. Clinical Practice Guidelines for Cervical Cancer. PMC10948982. 2024.
  8. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023. Cancer Res Treat. 2026. PMC13093029.
  9. HPV Genotyping in VaIN and Vaginal SCC. PMC8267732. Cancers. 2021.
  10. Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program in South Korea. Cancer Res Treat. 2024. PMC11261207.